DOSEGUY

Survodutide

most data

Also seen as: BI 456906

The Dose Guy’s verdict
Aug 28, 2026
3 sources

Solid numbers, wrong timing. Survodutide is a dual glucagon/GLP-1 agonist with real trial data, but on the gray market today there is no compelling reason to pick it over retatrutide or tirzepatide for weight loss. Where it earns attention is the liver: it is printing some of the strongest MASH and MASLD numbers in the field. If your interest is metabolic liver disease, watch this one. For weight loss alone, run one of the bigger two.

Would I take it?Not yet. Watch the liver story.

What it is

Survodutide is a dual agonist at the glucagon and GLP-1 receptors. Semaglutide hits GLP-1 alone. Retatrutide hits GLP-1, GIP, and glucagon. Survodutide lands between them: it gets the glucagon arm for energy expenditure but skips GIP. The glucagon side pushes the liver to burn stored fat directly, which is why the liver data looks strong even when the pure weight-loss numbers sit below the leaders. Boehringer Ingelheim’s candidate, with phase 3 results now landing.

What the research shows

The phase 2 numbers turned heads on the liver front. Phase 3 has now landed for both obesity and liver disease:

Phase 3 in obesity at 76 weeks: mean weight loss of 13.0% with survodutide 6.0 mg versus 5.4% with placebo.NEJM 2026 · phase 3 · n=725
Phase 2 in biopsy-confirmed MASH at 48 weeks: MASH improved without worsening fibrosis in 47% with 2.4 mg, 62% with 4.8 mg, and 43% with 6.0 mg, versus 14% with placebo.NEJM 2024 · phase 2 · n=293
Phase 3 in at-risk MASLD at 48 weeks: at least 30% liver fat reduction in 84.2% with survodutide 6.0 mg versus 24.3% with placebo.Nat Med 2026 · phase 3 · n=216

Realistic protocols

For pure weight loss, run retatrutide or tirzepatide instead. Survodutide’s gray-market niche, to the extent one exists, is the person tracking liver markers who wants the glucagon arm’s direct effect on liver fat. If you run it, pin it subcutaneously once a week, start low, raise only when needed, and give each dose a month.

Same class-wide rule on alcohol: the slowed gut makes drinking rougher, and the nausea is already heavier here than with the single-receptor compounds.

Start0.6 mg/wkSub-q. Low and slow.
Holdyour doseIf liver markers are moving and GI is tolerable, stay.
Raise+0.6 mgOnly when the response stalls. Give each step a month.
Ceiling6.0 mg/wkTrial max. More liver effect, but the GI cost is steep.

Side effects

Rougher GI than the single-receptor incretins, the trade for the glucagon arm:

commonNausea, diarrhea, and vomiting, at rates higher than semaglutide or tirzepatide. Dose-related, clustered around raises, but expect a harder ride overall.
monitorThe glucagon arm can raise resting heart rate, a known effect of the receptor class. Worth tracking, especially early.
monitorThe GLP-1 side carries the class-wide pancreatitis signal. Severe, persistent upper-belly pain means stop and get checked.
unknownNo cardiovascular outcomes trial exists, and no outcomes-length data exists beyond 76 weeks. The glucagon arm’s effect on lean mass over time is not yet characterized.

Where to buy

RUO.bio–
$98 / 10mg vial$9.80/mg
✓ verified Sep 12
Read review →
Visit →

Prices move. Links are affiliate links; they never change a ranking, and scores are set before the deal exists.